欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

已收盘 09-01 16:08:13

5.100

-0.070

-1.35%

最高5.275	最低5.100	成交量16.15万
今开5.170	昨收5.170	日振幅3.38%
总市值41.57亿	流通市值41.57亿	总股本8.15亿
成交额83.41万	换手率0.02%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":5.1,"timestamp":1788250093004,"preClose":5.17,"halted":0,"volume":161522,"delay":0,"changeRate":-0.013539651837524234,"floatShares":815000000,"shares":815000000,"eps":-0.23323323009369978,"marketStatus":"已收盘","change":-0.07,"latestTime":"09-01 16:08:13","open":5.17,"high":5.275,"low":5.1,"amount":834053,"amplitude":0.033849,"askPrice":5.1,"askSize":500,"bidPrice":5.09,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.17968871129493863,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788312600000},"marketStatusCode":5,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":5.17,"openAndCloseTimeList":[[1788226200000,1788235200000],[1788238800000,1788249600000]],"volumeRatio":0.502401,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477/tweets","defaultTab":"tweets","newsList":[{"id":"1100575152","title":"欧康维视生物-B：地塞米松眼用混悬注射液境内生产注册申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1100575152","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100575152?lang=zh_cn&edition=full","pubTime":"2026-09-01 20:01","pubTimestamp":1788264115,"startTime":"0","endTime":"0","summary":"2026年9月1日，欧康维视生物-B发布自愿性公告称，其核心药物OT-502的境内生产品种——地塞米松眼用混悬注射液的药品注册申请已获国家药品监督管理局药品审评中心按化药4类受理，并已申请纳入药品审评中心优先审评品种名单且完成公示程序。视姝是一种单剂量缓释的地塞米松眼用混悬液，用于治疗眼科术后炎症。若本次注册申请获批，公司将通过OT-502技术转移在中国内地生产地塞米松眼用混悬注射液，以取代现有的海外生产及进口模式。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664856154","title":"欧康维视生物-B(01477.HK)：境内生产的地塞米松眼用混悬注射液药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664856154","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664856154?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:59","pubTimestamp":1788263997,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147045285","title":"欧康维视生物-B：国产地塞米松眼内悬浊液药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1147045285","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147045285?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:59","pubTimestamp":1788263953,"startTime":"0","endTime":"0","summary":"欧康维视生物-B近日宣布，其自主研发的地塞米松眼内悬浊液药品注册申请已正式获得受理。欧康维视生物作为一家专注于眼科领域的创新药企，持续推进其产品管线，此次申请受理是其研发进程中的重要里程碑。欧康维视生物表示，将继续与监管机构保持密切沟通，推动该产品的审评进程，并致力于加速其他在研产品的开发，以满足眼科领域未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192737919","title":"欧康维视生物-B：地塞米松眼内悬浊液获药监局受理，列为化药四类","url":"https://stock-news.laohu8.com/highlight/detail?id=1192737919","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192737919?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:59","pubTimestamp":1788263950,"startTime":"0","endTime":"0","summary":"欧康维视生物-B（01477.HK）宣布，其地塞米松眼内悬浊液的上市申请已获国家药品监督管理局（NMPA）正式受理。该药品被归类为化学药品第4类，这一进展标志着公司在眼科治疗领域又迈出了重要一步。此次受理的申请，不仅凸显了该产品在中国市场的监管审批进程中的关键节点，也为公司未来在该细分市场的布局增添了新的砝码。随着监管流程的推进，该药物有望为相关眼科疾病患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664831619","title":"诺华制药(NVS.US)神经免疫管线“悲喜交加”：患者死亡致CAR-T临床试验暂停 MS口服药后期试验告捷","url":"https://stock-news.laohu8.com/highlight/detail?id=2664831619","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664831619?lang=zh_cn&edition=full","pubTime":"2026-09-01 15:40","pubTimestamp":1788248407,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华制药在神经与自身免疫领域迎来“冰火两重天”：公司因三名患者死亡紧急叫停八项CAR-T疗法临床试验;不过，其多发性硬化症口服药remibrutinib在后期临床试验中取得积极结果。CAR-T试验紧急暂停诺华制药在8月底暂停了八项针对自身免疫和神经系统疾病的实验性疗法临床试验，此前有三名患者死亡。诺华制药发言人表示，公司正在“对所观察到的安全事件进行全面审查”，并将这种致命免疫反应描述为CAR-T疗法中已知的安全风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BJT1NW94.SGD","IBBQ","MEDX","BK4578","PSYK","BK4585","BK4007","BMED","IE0002141913.USD","BK4532","BK1191","IE00B2B36J28.USD","IBBJ","LU0320765489.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU0070302665.USD","BK4588","01477","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","BK1574","PPH","MDTX","NVS","LU0211331839.USD","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664953831","title":"英硅智能逆势涨近6% 较年内低点已反弹超50% AI制药领域喜创佳绩 获北水持续加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2664953831","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664953831?lang=zh_cn&edition=full","pubTime":"2026-09-01 15:11","pubTimestamp":1788246717,"startTime":"0","endTime":"0","summary":"9月1日，英硅智能今日逆势上扬，盘中一度涨5.85%至46.3港元，较6月11日盘中创下的年内低点已累涨超50%，跑赢大盘表现。资金面上，英硅智能今年6月以来持续获南下资金青睐，港股通累计持仓比例由6月26日的5.92%逐步攀升至最新的25.09%，持仓比例显著提升。消息面上，英硅智能宣布，一项里程碑式研究已发表于《阿尔茨海默病与痴呆：阿尔茨海默病协会杂志》。","market":"sh","thumbnail":"http://imgcloud.jrjimg.cn/2026/09/cms_20260901151158042.jpg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2026/09/cms_20260901151158042.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/09/01151158314709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["VTHR","BK1191","QTOC","AGIX","BK1574","01477","ARTY","AIPO","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664357888","title":"英硅智能联席CEO任峰谈盈利可持续性：合作项目的积累是前提","url":"https://stock-news.laohu8.com/highlight/detail?id=2664357888","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664357888?lang=zh_cn&edition=full","pubTime":"2026-09-01 14:14","pubTimestamp":1788243250,"startTime":"0","endTime":"0","summary":"近日，英硅智能（03696.HK）交出上市以来首份半年报：2026年上半年总营收达1.06亿美元，同比大增287.2%；净利润3553.7万美元，一举扭转上年同期亏损1921.5万美元的局面，经调整净利润更高达5122.7万美元。这家去年底登陆港交所的AI制药公司，用半年时间完成了从持续投入期到自我造血能力的跨越。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013861395872.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013861395872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ARTY","03696","QTOC","BK1141","01477","CHAT","BK1574","AGIX","BK1191","AIPO","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664882712","title":"邦顺制药赴港IPO，创始团队出自华东医药，面临诺华、泽璟制药的竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2664882712","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664882712?lang=zh_cn&edition=full","pubTime":"2026-09-01 10:21","pubTimestamp":1788229285,"startTime":"0","endTime":"0","summary":"两年半累计亏损4.67亿","market":"fut","thumbnail":"https://img2.gelonghui.com/bf122-cc396b77-81ef-4c91-ae6d-db59d48043ce.jpg?guru_height=909&guru_width=1473&guru_size=100893","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/bf122-cc396b77-81ef-4c91-ae6d-db59d48043ce.jpg?guru_height=909&guru_width=1473&guru_size=100893"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6439376","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0196","REDS","BK1574","NVS","IE0002141913.USD","IPOS","IE0009355771.USD","BK4588","IE00BFTCPJ56.SGD","BK0187","LU0320765489.SGD","IE00B4R5TH58.HKD","LU0070302665.USD","FRHC","LU1969619763.USD","000963","BK4127","BK4532","BK0132","BK0183","BK0209","BK4007","IE00BJJMRZ35.SGD","KCE","BK0188","LU0211331839.USD","BK0175","MEDX","LU2328871848.SGD","PPH","LU0208291251.USD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4578","BK4585","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663006583","title":"歌礼制药-B(01672)发布中期业绩 股东应占亏损3.2亿元 同比增加263.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663006583","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663006583?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:24","pubTimestamp":1788182651,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布截至2026年6月30日止六个月业绩，该集团取得收入总额人民币5297.9万元，同比减少48.9%;研发成本3.42亿元，同比增加132.7%;公司权益股东应占亏损3.2亿元，同比增加263.5%;每股亏损30.74分。人体数据表明，ASC50有望成为同类首创及同类最佳口服小分子IL-17A抑制剂。ASC51为一款强效、选择性及每日一次口服STAT6降解剂并已具备向FDA 提交IND申请条件的候选药物。ASC52有望成为同类最佳IL-17AA、AF及FF口服环肽拮抗剂，预计将于2026年第四季度向FDA递交IND。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1574","BK1191","BK1515","BK1161","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150796215","title":"欧康维视生物-B（01477）OT-202在华III期试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1150796215","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150796215?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:27","pubTimestamp":1788172079,"startTime":"0","endTime":"0","summary":"2026年8月31日，欧康维视生物-B发布自愿性公告称，其自研用于治疗中至重度干眼症的同类首创新药OT-202在中国开展的III期临床试验已完成首例患者入组。首例患者入组被视为该项目在中国临床开发的重要里程碑。\\n\\n临床进展方面：\\n1. OT-202的I期临床试验于2023年2月顺利完成，结果显示在健康成人受试者中具有良好的安全性和耐受性。\\n2. II期临床试验自2023年2月启动，设计为随机、双盲、安慰剂对照研究，共在中国完成213名患者入组，并于2023年11月结束。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663074148","title":"欧康维视生物-B(01477)：OT-202 III期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2663074148","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663074148?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:26","pubTimestamp":1788171975,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，用于治疗干眼症的 OT-202于中国进行的III期临床试验已完成首例患者入组。首例患者成功入组标志着OT-202在中国临床开发的一项重要里程碑，并体现集团为干眼症患者推进创新疗法的承诺。OT-202的II期临床试验，已于2023年11月于中国完成合共213名患者的II期临床试验入组。OT-202的II期临床试验结果已在国际顶尖眼科期刊《Ophthalmology》发表。2024年3月，OT-202的II期临床试验达到其主要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BMED","01477","IBBQ","PSYK","IBBJ","MDTX","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663023533","title":"【新股IPO】邦顺制药向港交所主板提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2663023533","media":"金吾财讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663023533?lang=zh_cn&edition=full","pubTime":"2026-08-31 08:43","pubTimestamp":1788136993,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所8月30日披露，邦顺制药向港交所主板提交上市申请，中信建投国际为独家保荐人。财务方面，公司于2024至2025年以及2026年上半年，分别录的亏损8844.4万元、2.99亿元以及8015.5万元。股东层面，截至最后实际可行日期，李邦良通过杭州万裕和、杭州三睿和杭州六因泰持有公司约31.25%的投票权。","market":"us","thumbnail":"https://static.szfiu.com/news/20220324/ZDg5MGY3YjA4MWNiNDkyZjgyMTczYjhiYWU0ZDI5OWEyNTc1MTQyMDQxMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/ZDg5MGY3YjA4MWNiNDkyZjgyMTczYjhiYWU0ZDI5OWEyNTc1MTQyMDQxMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989965","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FRHC","HEXmain","KCE","BK1574","BK4127","01477","BK1191","REDS","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663040910","title":"新股消息 | 邦顺制药二次递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2663040910","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663040910?lang=zh_cn&edition=full","pubTime":"2026-08-31 06:57","pubTimestamp":1788130620,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663442710","title":"邦顺制药冲刺港股：年亏3亿 李邦良控制31%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2663442710","media":"雷递网","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663442710?lang=zh_cn&edition=full","pubTime":"2026-08-30 22:30","pubTimestamp":1788100218,"startTime":"0","endTime":"0","summary":"杭州邦顺制药股份有限公司（简称：“邦顺制药”）日前更新招股书，准备在港交所上市。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260830/6392372580177336339063505.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260830/6392372580177336339063505.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34989/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK1574","KCAI","BK4585","VXUS","BK4588","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663415150","title":"歌礼制药-B(01672)：每日一次口服小分子GLP-1受体激动剂ASC30用于长期体重管理的全球III期临床项目完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2663415150","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663415150?lang=zh_cn&edition=full","pubTime":"2026-08-30 18:08","pubTimestamp":1788084524,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，ASC30用于长期体重管理的全球III期临床项目已完成首例受试者给药。ASC30是一款歌礼专有的、正在临床研究中的每日一次口服小分子胰高血糖素样肽-1受体激动剂，开发用于长期体重管理和糖尿病治疗。歌礼预计将于2028年第三季度公布AURORA III期临床项目的顶线数据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489037.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","BK1191","BK1161","01477","JDOC","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663046742","title":"深度｜AI制药进入验证期：百万高薪人才难觅，吃到红利的第一波企业出现了","url":"https://stock-news.laohu8.com/highlight/detail?id=2663046742","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663046742?lang=zh_cn&edition=full","pubTime":"2026-08-30 15:27","pubTimestamp":1788074879,"startTime":"0","endTime":"0","summary":"在近期药企的财报交流会上，AI制药话题密集被提及。翰雨医药咨询（上海）有限公司Healthview合伙人李思春对AI制药有着更直观感受，因为行业的景气度，写在了招聘启事里。作为医药猎头，他服务的客户抛出的AI制药岗位需求增多，尤其是从去年到现在，这种现象更加明显，符合条件的人才并不好招，合适的候选人也容易被截胡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608303859386484.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608303859386484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["VTHR","QTOC","01477","CHAT","AGIX","AIPO","BK1191","BK1574","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663409206","title":"欧康维视生物-B(01477.HK)发布中期业绩，经调整亏损净额5752.3万元 同比减少46.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663409206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663409206?lang=zh_cn&edition=full","pubTime":"2026-08-29 00:02","pubTimestamp":1787932956,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663061092","title":"欧康维视生物-B(01477)发布中期业绩，经调整亏损净额5752.3万元 同比减少46.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663061092","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663061092?lang=zh_cn&edition=full","pubTime":"2026-08-29 00:02","pubTimestamp":1787932956,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B(01477)发布截至2026年6月30日止6个月中期业绩，该集团取得收益4.24亿元，同比增加44.1%;经调整亏损净额5752.3万元，同比减少46.74%;每股亏损0.12元。公告称，收益大幅增加主要是由于销售眼科产品(包括优施莹®、适利达®、适利加®、爱赛平®及于Alcon交易项下自Alcon收购及授权引进的产品)产生的收入大幅增加;及以销售为基础的特许权使用费收入显著增加，主要由博优景®的成功商业化所驱动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198202086","title":"欧康维视生物-B（01477）调整资金用途　1.03亿元IPO余款及1,937万港元配售款转投营运资金","url":"https://stock-news.laohu8.com/highlight/detail?id=1198202086","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198202086?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:22","pubTimestamp":1787926945,"startTime":"0","endTime":"0","summary":"8月28日，欧康维视生物-B公告称，董事会已决议调整部分募集资金用途，并将未动用的首次公开发售及配售所得款项合计约1.22亿港元重新分配至“营运资金及其他一般企业用途”，以匹配公司当前业务发展需求。截至2026年6月30日，已使用7.62亿元，占97.5%；尚余19.37百万港元未动用。董事会称，此次资金用途调整不会对现有业务造成重大不利影响，符合公司及股东整体利益。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148920071","title":"欧康维视生物-B2026年上半年营收4.24亿元，净利润-0.58亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1148920071","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148920071?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:16","pubTimestamp":1787926578,"startTime":"0","endTime":"0","summary":"2026年上半年，欧康维视生物-B实现营收人民币4.24亿元，同比增长44.1%。同期经调整净利润为-0.58亿元，与去年同期相比亏损收窄46.7%。销售及营销费用约1.60亿元，占总营收的37.7%；管理费用约0.91亿元，占总营收的21.6%。报告期内，经调整EBITDA约0.23亿元，上年同期为-0.40亿元。报告期内，眼科产品仍是主要收入来源，销售收入约3.77亿元，较去年同期的2.85亿元增加约0.92亿元；销售相关的特许权使用费收入约0.44亿元，较去年同期的约0.02亿元大幅增长。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"欧康维视生物-B2026年上半年营收4.24亿元，净利润-0.58亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":-0.0058},{"period":"1month","weight":0.0217},{"period":"3month","weight":-0.1193},{"period":"6month","weight":-0.1984},{"period":"1year","weight":-0.4198},{"period":"ytd","weight":-0.3014}],"compareEarnings":[{"period":"1week","weight":0.0019},{"period":"1month","weight":-0.0123},{"period":"3month","weight":-0.0181},{"period":"6month","weight":0.0126},{"period":"1year","weight":0.0195},{"period":"ytd","weight":-0.0025}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症（DED）、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.097698},{"month":2,"riseRate":0.5,"avgChangeRate":-0.037557},{"month":3,"riseRate":0.5,"avgChangeRate":0.044668},{"month":4,"riseRate":0.5,"avgChangeRate":0.015642},{"month":5,"riseRate":0.5,"avgChangeRate":0.087204},{"month":6,"riseRate":0.666667,"avgChangeRate":0.062947},{"month":7,"riseRate":0.5,"avgChangeRate":-0.003589},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.052517},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.082685},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.121217},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}